Beneficial Ownership Report · SCHEDULE 13G
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- bioAffinity Technologies, Inc.
- Company CIK
- 0001712762
- Street
- 3300 NACOGDOCHES ROAD
- Street (continued)
- SUITE 216
- City
- SAN ANTONIO
- State / country code
- TX
- Postal code
- 78217
Statement details
- Security class
- Common Stock
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- HRT FINANCIAL LP
- Citizenship / organization
- DE
- Reporting person type
- BD
- Aggregate amount owned
- 127,132.00
- Percent of class
- 10.9
- Sole voting power
- 127,132.00
- Shared voting power
- 0.00
- Sole dispositive power
- 127,132.00
- Shared dispositive power
- 0.00
- Comments
- The percentage reported herein is based on 1,166,625 shares of Common Stock outstanding as of September 30, 2026, as reported by bioAffinity Technologies, Inc. in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on November 6, 2026, plus 986 shares of Common Stock issuable upon the exercise of certain warrants held by HRT Financial LP, for a denominator of 1,167,611 shares.
Item 1
Issuer
bioAffinity Technologies, Inc.
Principal executive office address
3300 NACOGDOCHES ROAD, SUITE 216, SAN ANTONIO, TEXAS, 78217.
Item 2
Citizenship
Delaware
Filing person
HRT Financial LP, a Delaware limited partnership
Principal business or residence address
c/o Hudson River Trading LLC, 3 World Trade Center, 175 Greenwich Street, 76th Floor, New York, NY 10007
Item 3
Not applicable indication
N
Type of filing person
BD
Item 4
Percent of class
The response to Row 11 of the cover page is incorporated herein by reference and sets forth the information required by this item.
Amount beneficially owned
The ownership information reported herein is as of September 30, 2026. The reported aggregate amount includes 126,146 shares of Common Stock held directly and 986 shares of Common Stock issuable upon the exercise of certain warrants held by the Reporting Person. The response to Row 9 of the cover page is incorporated herein by reference and sets forth the information required by this item.
Sole voting power
The response to Row 5 of the cover page is incorporated herein by reference and sets forth the information required by this item.
Shared voting power
The response to Row 6 of the cover page is incorporated herein by reference and sets forth the information required by this item.
Sole dispositive power
The response to Row 7 of the cover page is incorporated herein by reference and sets forth the information required by this item.
Shared dispositive power
The response to Row 8 of the cover page is incorporated herein by reference and sets forth the information required by this item.
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- HRT FINANCIAL LP
- Signed
- Adam Nunes
- Title
- CEO
- Date
- 11/19/2026
Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.